Johnson & Johnson debuts next-generation Shockwave C2 Aero Fly coronary IVL catheter, aiming to cut calcium treatment time

Johnson & Johnson on Tuesday announced a next-generation coronary catheter for calcium modification, rolling out the Shockwave™ C2 Aero Fly Coronary IVL catheter with a stated goal of shortening procedure time for patients with calcified coronary artery disease.

In the company’s announcement, the device is described as an “IVL” catheter, meaning it uses intravascular lithotripsy, a technique that passes energy through a small balloon-like system inside a blood vessel to fracture calcium and improve how well physicians can prepare the artery for further treatment such as stent placement.

Johnson & Johnson said the new catheter delivers pulses at 2 Hz, a change positioned as an efficiency improvement versus earlier system configurations. The company’s announcement also stated that it is intended to cut IVL treatment time in half, reflecting an emphasis on workflow and procedural efficiency in catheter-based care.

The product is marketed specifically for coronary use, targeting calcium modification in the coronary arteries where hardened plaque can limit expansion during angioplasty and stenting. In practice, calcification is a common challenge in interventional cardiology, and manufacturers have pursued different catheter designs and energy delivery approaches to reduce the time and energy needed to achieve adequate calcium cracking.

While Johnson & Johnson did not provide clinical trial performance metrics in the brief report, the company’s framing centers on pulse delivery and treatment-duration reduction. Details such as the magnitude of the time savings in specific patient subgroups, measured procedural endpoints, and any comparative data versus prior Shockwave catheter versions were not included in the publication that carried the announcement.

Johnson & Johnson’s MedTech business has been building out its cardiovascular franchise around intravascular lithotripsy, a category in which device performance, consistency of lesion preparation, and procedural logistics are closely watched by hospitals and clinicians. Faster treatment cycles can matter for cath lab throughput and for patients when procedures run longer than expected, though the announcement does not quantify these potential operational benefits.

For healthcare providers and payers, the key question will be how the 2 Hz pulse configuration translates into real-world procedure times and outcomes across diverse lesion types. The post also does not specify whether the “cut in half” claim is based on a single study, pooled data, or internal benchmarking, nor does it describe regulatory status by geography, hospital adoption timelines, or pricing and reimbursement terms.

As the product moves through adoption, observers will likely look for additional disclosure around comparative effectiveness, safety indicates, and device compatibility with existing catheter lab workflows. Johnson & Johnson did not spell out those items in the reported announcement, leaving room for later updates from the company or from regulatory submissions.